Caduet Related Published Studies
Well-designed clinical trials related to Caduet (Amlodipine / Atorvastatin)
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. [2005.01.15]
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. [2004.09]
Well-designed clinical trials possibly related to Caduet (Amlodipine / Atorvastatin)
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. [2001.06]
Other research related to Caduet (Amlodipine / Atorvastatin)
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. [2008.01]
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. [2008]
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. [2008]
A single-pill combination of amlodipine besylate and atorvastatin calcium (update). [2007.03]
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. [2006.09]
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). [2006.06.16]
A single-pill combination of amlodipine besylate and atorvastatin calcium. [2006.03]
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. [2005.07]
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). [2005.05]
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. [2004.09]
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. [2004.02]
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. [2003.09]
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. [2003.07]
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. [2002.09]
Other possibly related research studies
[First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT-BPLA results] [2005.10]
A rationale for combination therapy in risk factor management: a mechanistic perspective. [2005.12]
Interactions between grapefruit juice and cardiovascular drugs. [2004]
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. [2003.11]
Pharmacotherapy for dyslipidaemia--current therapies and future agents. [2003.11]
Gateways to clinical trials. [2002.10]
Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. [2002.06]
Gateways to Clinical Trials. June 2002. [2002.06]
[An overview of hypertension studies with calcium antagonists] [1999.05.20]
Fixed-dose combination therapy with statins : strengths, limitations, and clinical and regulatory considerations. [2008]
|
